The authors determined the factors that affected survival in prostate cancer patients with bone tumors when treated with zoledronic acid (Zometa, INN, Reclast). 

This study looked at the effect, and specifically drug related toxicities, of cabazitaxel (jevtana) plus prednisone treatment in metastatic prostate cancer patients.

The authors aimed to determine factors associated with weight gain in patients who received hormone therapy.  

This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these patients.

This study compared the safety and effectiveness of two forms of imaging-guided radiation techniques for prostate cancer. Researchers reported more favorable outcomes with intensity modulated radiation therapy (IMRT) than with 3-dimensional conformal radiation therapy (3DCRT).

This study evaluated whether the presence of intraductal carcinoma of the prostate (IDC-P) in prostate biopsies predicts a poorer prognosis.

The authors aimed to determine whether age had an effect on patient quality of life after localized prostate cancer treatment.

This review examines the current and future treatment options for metastatic castration-resistant prostate cancer.

This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment improved patients’ survival in these patients.